Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EchoStar Corporation Common Stock (ECHO) vs Gilead Sciences, Inc. (GILD) Price & Performance

EchoStar Corporation Common StockTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

EchoStar Corporation Common Stock vs Gilead Sciences, Inc. — how do they compare? EchoStar Corporation Common Stock trades at $95.25 (market cap $28.41B), while Gilead Sciences, Inc. trades at $147.1 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 6.4× EchoStar Corporation Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while EchoStar Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 0 Days and Gilead Sciences, Inc. for 111 Days on average.

ECHOGILD
Market Cap
$28.41B$182.09B
Volume
3,258,2954,960,247
Sector
MediaHealth
52-Week High
$141.80$155.80
52-Week Low
$66.93$116.74
Typical Hold Time
0 Days111 Days
Enterprise Value
$45.47B$205.15B
Dividend Yield
—2.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EchoStar Corporation Common Stock

No Aura AI signal available yet.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.

Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ECHO
100% Buy0% Sell
Avg holding period · 0 Days
GILD
100% Buy0% Sell
Avg holding period · 111 Days

About EchoStar Corporation Common Stock

EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.

Read more on ECHO →

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD →